Accenture vs Concentrix
ACN and CNXC side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACN and CNXC compare
Accenture is the larger company, worth 94 times as much as Concentrix ($172B against $1.8B).
Accenture grew revenue faster over the last twelve months (6.5% versus 2.6% for Concentrix).
Accenture keeps more of each dollar of sales as profit, with a net margin of 11.3% compared with −24.0% at Concentrix.
Both pay dividends: Accenture yields 1.9% and Concentrix 4.8%.
Accenture scores higher on the StockData Score (19 against 9 for Concentrix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACN | CNXC |
|---|---|---|
| Size and price | ||
| Market cap | $172B | $1.8B |
| Share price | $258.24 | $30.13 |
| Change, 1 year | 4.2% | −29.4% |
| Change, 5 years | −29.9% | −82.8% |
| Beta (5Y) | 0.96 | 1.01 |
| Employees | 814K | 455K |
| StockData Score | ||
| Total score | 19 (better) | 9 |
| Valuation score | 4 (better) | 3 |
| Growth score | 2 (better) | 1 |
| Performance score | 6 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 2 | 4 (better) |
| Valuation | ||
| P/E | 19.0× | – |
| P/S | 2.3× | 0.2× (better) |
| P/B | 5.5× | 1.0× (better) |
| EV/EBITDA | 15.0× | – |
| P/FCF | 14.8× | 3.2× (better) |
| PEG | 2.39 | – |
| FCF yield | 6.7% | 31.3% (better) |
| Fair value | $307.54 | $101.99 |
| Margin of safety | 16.0% | 70.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 6.5% (better) | 2.6% |
| Revenue growth, 5Y average | 8.0% | 15.8% (better) |
| Net income growth (TTM) | 9.0% (better) | −856% |
| EPS growth (TTM) | 11.6% (better) | −921% |
| EPS growth, 5Y average | 8.2% | – |
| Profitability | ||
| Gross margin | 32.0% | 34.1% (better) |
| Operating margin | 15.4% (better) | −20.9% |
| Net margin | 11.3% (better) | −24.0% |
| FCF margin | 15.7% (better) | 5.8% |
| Return on equity | 26.7% (better) | −78.2% |
| Return on invested capital | 31.8% (better) | −22.3% |
| Financial health | ||
| Debt / equity | 0.32 (better) | 2.47 |
| Net debt / EBITDA | −0.24 | – |
| Interest coverage | 37.6× | – |
| Current ratio | 1.43 (better) | 1.23 |
| Altman Z-score | 4.68 (better) | 0.38 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 1.9% | 4.8% (better) |
| Buyback yield | 4.4% | 5.4% (better) |
| Shareholder yield | 6.3% | 10.2% (better) |
| Ownership | ||
| Held by institutions | 73.2% | 112% |
| Held by insiders | 0.04% | 13.1% |
| Insider net buying, 12 months | −$11.8M (better) | −$133M |
| Superinvestors holding | 5 (better) | 1 |
| Short interest, % of float | 3.0% | 17.3% |
Go deeper
- ACN stock overview
- ACN income statement
- ACN valuation and score
- CNXC stock overview
- CNXC income statement
- CNXC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.